Outpost Bio raises $3.5M pre-seed for human microbiology models

Outpost Bio, a company focused on decoding complex interactions in human biology, has raised a $3.5 million pre-seed round co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC, Defined, and several strategic family offices and angel investors.

Human microbiology examines how microbial communities living in and on the body metabolise drugs, process nutrients, and influence health outcomes. Despite being one of the most complex and data-rich areas in biology, it remains difficult for R&D teams to translate this complexity into actionable insights. While many biological frontier models focus primarily on components encoded in human DNA, biological function emerges from interactions across multiple systems.

Outpost Bio aims to address this gap by developing frontier models at the interaction layer with a focus on human microbiology. Its Lab-in-the-Loop platform combines automated experimentation with machine learning to create a closed feedback loop in which models learn from experimental results and guide subsequent testing.

The approach generates proprietary, human-derived functional data at scale, supporting pharmaceutical partners in reducing clinical risk, designing safer formulations, and strengthening regulatory evidence.

Beyond pharmaceuticals, food and consumer companies can use the platform to assess how prebiotics, botanicals, and other ingredients influence microbial communities.

The new funding will support the further development of Outpost Bio’s experimental and modelling platforms, enabling new approaches to the design of drugs, ingredients, and consumer health products.